Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agencourt Bioscience, a wholly-owned subsidiary of Beckman Coulter, has announced that its Genomic Services received a major sequencing contract for the National Cancer Institute, part of the National Institutes of Health.
Subscribe to our email newsletter
Under the agreement, the National Cancer Institute (NCI) will supply Agencourt with normal and cancer tumor tissue samples and periodic lists of genes and targeted regions to be sequenced. The goal of the project is to provide NCI research collaborators with a consistent, cost-effective, high-throughput sequencing resource. The initial term of the contract is one year, with an option to renew for a second year.
Collaborators will submit sequence trace data to the National Center for Biotechnology information (NCBI) and the base calls will be placed in a database managed by the NCI. Agencourt will also develop a special web site that is accessible by project collaborators.
This web site, with the posted information, will allow NCI collaborators to query the NCBI Trace database for additional metadata and relate it to other experimental results and clinical data by bio-specimen ID. The project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health.
Erick Suh, director, Genomic Services, said: “We are delighted to be selected as the provider for this important project, which may lead to better treatment of cancer.”